ASTRO updates radiation oncology safety guide
The American Society for Radiation Oncology (ASTRO) has published an updated...Read more on AuntMinnie.comRelated Reading: ASTRO lauds selection of Shah for senior role at CMS ASTRO releases new prostate radiation therapy guideline ASTRO elects new board president-elect Radiation oncologists prepare to meet with Congress ASTRO urges CMS to shorten MIPS reporting period
Publication date: Available online 13 July 2020Source: Journal of Vascular and Interventional RadiologyAuthor(s): Eric M. Chang, Narek Shaverdian, Nina Capiro, Michael L. Steinberg, Ann C. Raldow
Authors: Othman S, Azoury SC, Weber KL, Kovach SJ Abstract Neoadjuvant treatment and surgical resection for sarcoma patients can often leave devastating wounds necessitating soft-tissue coverage in the form of free flaps. There is still debate as to the optimal flap for reconstruction of defects in irradiated fields. We aim to describe our experiences with free fasciocutaneous and free muscle flaps for sarcoma reconstruction in the setting of radiation therapy. A retrospective chart review was conducted encompassing all patients requiring soft-tissue reconstruction secondary to sarcoma resection from January 2010 t...
In this report, we describe a case of malignant prolactinoma with liver metastases masquerading as metastatic gastrointestinal stromal tumor (GIST). A 54–years–old woman received dopamine agonists for macroprolactinoma for 2 years, followed by transsphenoidal surgery due to a poor response to medical therapy. Despite the continuation of dopamine agonist after surgery, serum prolactin level progressively increased to above 8,000 ng/ml in 5 years. There was no evidence of disease recurrence on sella magnetic resonance imaging (MRI). She stopped medical therapy. Meanwhile, she was diagnosed with GIST accompanied b...
Nasopharyngeal carcinoma (NPC) is the most common head and neck cancer in southern China. Radiotherapy is the primary therapeutic approach for NPC, rather than surgery. With the wide application of intensity-modulated radiation therapy (IMRT), better treatment outcomes of NPC patients were achieved in modern era. But distant metastasis and local-regional relapse are still the causes of treatment failure, especially the former [1 –4]. Screening NPC patients with a high risk of distant metastases and local-regional relapse has implications for making informed decisions about NPC treatment.
Cancer survival rates are generally increasing worldwide , making survivorship research a key component of cancer care. The growing number of cancer survivors includes a large fraction of long-term survivors; in the United States, 45% of the 16.9 million people with a history of cancer who were alive in 2019 had been diagnosed more than 10 years ago . Understanding determinants of second primary cancer risks among long-term survivors is essential for patient information, screening and/or prophylactic procedures, depending on the site, and requires large studies with detailed treatment information.
Soft tissue sarcomas (STS) represent a rare and heterogeneous group of malignant diseases . They arise most often in the extremities and trunk ( ∼55%), followed by the retroperitoneal/intraabdominal space (∼35%) and the head and neck region (∼10%) . The most important prognostic factors include tumour grade, tumour size, location (deep vs. superficial) and resection margin [2,3]. Complete surgical removal is the cornerstone of curat ive intent treatment, although its extent has been subject to change in the last decades .
Radiation treatment planning is difficult in gastric cancer patients because of the close adjacency to organs at risk, e.g., the liver, kidney, intestine, lung, heart and spinal cord. The radiobiological exploration of the side effects of radiation therapy in organs at risk, as well as risk doses and clinical factors, which have an influence on radiation damage, is crucial in terms of the safety of radiotherapy. Currently, the QUANTEC (Quantitative Analysis of Normal Tissue Effect in the Clinic) protocols  and Timmerman guidelines  concerning ablative doses are basic documents that are applied in radiotherapy planning.
Radiation therapy for head neck cancers (HNCs) at the skull base can result in high doses of radiation delivered to the brain, potentially leading to radiation-associated image changes (RAIC) (1). Often the diagnosis of RAIC is based solely on radiographic findings on post-treatment MRIs obtained for routine cancer surveillance purposes. For HNCs, information on RAIC stems largely from studies in patients with nasopharyngeal cancers (NPC) treated with Intensity Modulated Radiation Therapy (IMRT), with reported incidences of temporal lobe RAIC ranging between 2% and 14% (2 –12).
With great interest, we have read the publication of Vitullo et al, regarding the use of simulation-CT ’s as an opportunistic coronavirus disease 2019 screening tool during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic (1). Within the Iridium Network, a radiation therapy (RT) department consisting of 10 linear accelerators, a very similar approach (Figure 1) was adopted. In this short communication, we want to describe our methodology and report the outcome in a population of 724 patients.
Although a high-dose Radiation Therapy (RT) exposure of the chest and mediastinum represents an effective medical treatment for many tumours, adverse effects on hearth and vessels, also defined as Radiation Induced Heart Disease (RIHD), might arise [1 –3].